Search results
Izokibep shows promise in psoriatic arthritis trial By Investing.com
Investing.com· 3 days agoACELYRIN, INC. (NASDAQ: SLRN), a biopharmaceutical company specializing in immunology, announced...
AbbVie’s RINVOQ now indicated for paediatric arthritis in US
Pharmaceutical Technology via Yahoo Finance· 3 days agoAbbVie has announced that its RINVOQ (upadacitinib) is now indicated for treating polyarticular...
FDA Extends Upadacitinib Indications to Kids With Arthritis
Medscape· 4 days agoThe JAK inhibitor's safety profile for patients as young as 2 years was similar to known to the...
Rhode Islanders face massive barriers to health care | Opinion
The Providence Journal via Yahoo News· 2 days agoPaul Adam, of Woonsocket, is the Rhode Island Lead Volunteer for the American Cancer Society Action Network. Psoriatic arthritis controlled my life, taking ...
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Zacks via Yahoo Finance· 18 hours agoSkyrizi is already approved in the United States and the EU for treating plaque psoriasis, psoriatic...
Inebilizumab 'MITIGATES' Flare Risk in IgG4-Related Disease
Medscape· 1 day agoInebilizumab-cdon reduced the risk for flares by 87% in patients with IgG4-RD, the MITIGATE study showed.
Simponi and Simponi Aria cost: Reducing long-term costs and more
Medical News Today· 5 days agoSimponi and Simponi Aria both contain the active ingredient golimumab. A biosimilar medication is a...
How Can Cardiovascular Risk Be Reduced in Kidney Dialysis?
Medscape· 3 days agoNew data on clazakizumab, a monoclonal antibody targeting interleukin-6 (IL-6), and home...
My patients can’t afford two crucial medications, and Big Pharma should be held accountable
Colorado Newsline via Yahoo News· 2 days agoAs a physician, I am encouraged and impressed with the work that Colorado’s Prescription Drug...
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
Zacks via Yahoo Finance· 5 days agoAbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing...